APTOSE BIOSCIENCES INC (APTO)

Aptose Announces Results from Special Meeting of Shareholders

Aptose Announces Results from Special Meeting of Shareholders

Aptose Announces Results from Special Meeting of Shareholders ...

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib...

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Announces Adjournment of its Special Meeting of Shareholders...

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024

APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the second quarter o...

Aptose Reports Results for the Second Quarter 2024

Aptose Reports Results for the Second Quarter 2024

Aptose Reports Results for the Second Quarter 2024...

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders...

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress...

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules ...

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules ...

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024

APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the first quarter of...

Aptose Reports Results for the First Quarter 2024

Aptose Reports Results for the First Quarter 2024

Aptose Reports Results for the First Quarter 2024 ...

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 ...

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023

APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the fourth quarter o...

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose Reports Results for the Fourth Quarter and Full Year 2023 ...

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 ...

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose closes previously announced public offering and private placement...

Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts

Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024!